Search clinical trials for: paclitaxel apatinib S-1

Total 1017 results

Shandong University
The Affiliated Hospital of Qingdao University; Qianfoshan Hospital; The Second...

Recruiting

Antineoplastic Drugs in Elderly Patients

Cancer

China
Changzhou Cancer Hospital of Soochow University

Completed

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer (EASE)

Non-small Cell Lung Cancer

China
Hebei Medical University

Not yet recruiting

A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer
Hebei Medical University

Unknown

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma

Refractory or Metastatic Esophageal Squamous Cell Carcinoma

China
Beijing Friendship Hospital

Unknown

Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Affiliated Hospital of Qinghai University

Unknown

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

Gastric Cancer

China
Chinese PLA General Hospital

Unknown

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Gastric Cancer

China
Beijing Friendship Hospital

Completed

Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer

Gastric Cancer
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Yang Jianjun, PhD

Recruiting

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Advanced Gastric Cancer

China
China International Medical Foundation
Chinese Society of Clinical Oncology

Unknown

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies (Y-HR2017-025)

Head and Neck Cancer

China
Changzhou No.2 People's Hospital

Unknown

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer (ASPC)

Advanced Pancreatic Cancer
Chang Gung Memorial Hospital

Recruiting

Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma (GAS)

Metastatic Pancreatic Adenocarcinoma

Taiwan
Brown University
Rhode Island Hospital; Memorial Hospital of Rhode Island

Terminated

A Study of Dasatinib With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
Qingdao Municipal Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer
Tianjin Medical University Cancer Institute and...

Completed

Chemotherapy Combined With Apatinib and PD-1 Antibody

Gastric Cancer

China
Tomoshi Tsuchiya

Completed

A Feasibility Study of Oral Adjuvant Chemotherapy With S-1

Non-small Cell Lung Cancer

Japan
China Medical University, China

Unknown

Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer

Advanced Gastric Cancer

China
Fudan University
The First Affiliated Hospital of Anhui Medical University; Guangdong Provincial... and other collaborators

Withdrawn

Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.

Gastric Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Cancer Institute and Hospital, Chinese Academy...

Terminated

First Line Chemotherapy for Advanced Cancer (GC-A-003)

Gastric Cancer

China
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Pfizer

Completed

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Neoplasms

Poland, United States, Spain
Shanghai Ninth People's Hospital Affiliated to...

Completed

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Unknown

Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer (CAPITAL)

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

Gastric Cancer

China
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Breast Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Brain and Central Nervous System Tumors | Bladder Cancer | Extragonadal Germ Cell Tumor

United States
Zhejiang Cancer Hospital

Completed

S-1 and Radiotherapy in Elderly Patients With Esophageal Cancer

Esophageal Cancer

China
Asan Medical Center

Withdrawn

Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) (IDEAL-E)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Korea, Republic of
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer
Hamamatsu University

Unknown

Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Colon Cancer

Japan
Sun Yat-sen University

Completed

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Gastric Cancer

China
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Taiho Oncology, Inc.
Quintiles, Inc.; United BioSource, LLC

Completed

Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer

Locally Advanced or Metastatic Pancreatic Cancer
TTY Biopharm
National Taiwan University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Terminated

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

Pancreatic Cancer | Adjuvant Chemotherapy | Resected Pancreatic Cancer

Taiwan
Fudan University

Completed

S-1 Combined With IMRT Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Seoul National University Bundang Hospital

Unknown

S-1-induced Lacrimal Drainage Obstruction

Gastric Cancer

Korea, Republic of
Japan Clinical Cancer Research Organization
Kitasato University

Completed

Clinical Trial of Chemosensitivity Test

Gastric Cancer

Japan
Fudan University

Not yet recruiting

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Advanced Pancreatic Cancer

China
Zhejiang Cancer Hospital

Unknown

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

Drug Safety | Surgically-Created Resection Cavity

China

3

Subscribe